Advances in perioperative planning, surgical technique, and postoperative care over the past two decades have allowed the indications for hepatic resection to be potentially broadened to include histologies and/or disease burdens previously felt to be contraindications for this treatment modality. This trend has been seen most notably with respect to resection of colorectal-related liver metastases.[1, 2] Historically, colorectal liver metastases have been treated with palliative chemotherapy. The improvements seen with surgical resection have made this the gold standard for treatment; expected 5-year survival rates are 50% to 65%, and resection offers the only potential for cure.[3] Hepatic resection for neuroendocrine-related liver metastases is likewise now accepted as appropriate.[4] However, while retrospective reports have demonstrated long-term survival in some highly selected patients with other histologies, including melanoma and breast cancer, the application of hepatectomy in these patients remains controversial.